The Phase 3 ACCEL clinical trial represents important progress in Ardelyx’s goal of expanding the patient population who may benefit from IBSRELA, beyond its lead indication for irritable bowel ...

Ardelyx recently dosed the first patient in ACCEL, a large Phase 3, 26-week, placebo-controlled trial evaluating IBSRELA (tenapanor) in about 700 adults with chronic idiopathic constipation, aiming to ...

A survey, published in Advances in Therapy, collected data on the needs of chronic idiopathic constipation patients, in an attempt to gauge what patients and providers thought about the disease.

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, will present new findings at the American College of Gastroenterology (ACG) 2024 Annual ...

The Food and Drug Administration on Thursday approved New York City-based Synergy Pharmaceuticals’ drug for chronic idiopathic constipation. Trulance is a once-daily treatment that works locally in ...

Austin, TX, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Vibrant Gastro announced today the publication of new real-world evidence in Clinical and Translational Gastroenterology demonstrating the long-term ...

Please provide your email address to receive an email when new articles are posted on . ACG and AGA recommend polyethylene glycol, sodium picosulfate, linaclotide, plecanatide and prucalopride for ...

(CNN) — Do you often experience difficulty defecating? If the answer is yes, newly released recommendations may help relieve your symptoms. Kiwifruit, rye bread and high mineral-content water can help ...

Millions of adults all over the world endure chronic constipation — an awkward situation marked by hard, painful, or infrequent bowel movements which disrupt daily life. Even though prevalent, advice ...

NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced new insights that highlighted the frustrations many patients with chronic idiopathic constipation (CIC) feel with ...